Table 2.
Comparison of prognostic models for DFS in our cohort using different combinations of CPs and molecular biomarkers
| Model, formula, and features | HR (95%CI) | P value | AIC | LRT P value |
| Model 1: CP features | ||||
| Tumor size (> 2.0 cm vs. ≤ 2.0 cm) | 2.51 (1.31-4.80) | 0.005 | 553.42 | < 0.001** |
| ALN status (positive vs. negative) | 1.67 (0.96-2.93) | 0.071 | ||
| ER (negative vs. positive) | 2.24 (1.26-4.00) | 0.006 | ||
| Model 2: CP features + TILs | ||||
| Tumor size (> 2.0 cm vs. ≤ 2.0 cm) | 2.51 (1.32-4.80) | 0.005 | 545.28 | < 0.001** |
| ALN status (positive vs. negative) | 1.77 (1.01-3.11) | 0.045 | ||
| ER (negative vs. positive) | 2.15 (1.21-3.84) | 0.009 | ||
| TILs (low vs. high) | 2.53 (1.39-4.61) | 0.002 | ||
| Model 3: CP features + TILs + CNA | ||||
| Tumor size (> 2.0 cm vs. ≤ 2.0 cm) | 2.51 (1.31-4.78) | 0.005 | 545.73 | < 0.001** |
| ALN status (positive vs. negative) | 1.87 (1.06-3.30) | 0.030 | ||
| ER (negative vs. positive) | 2.15 (1.20-3.83) | 0.010 | ||
| TILs (low vs. high) | 2.44 (1.33-4.46) | 0.004 | ||
| CNA (high vs. low) | 1.42 (0.81-2.48) | 0.216 | ||
| Model 4: CP features + TILs + TRAG (our novel model) | ||||
| Tumor size (> 2.0 cm vs. ≤ 2.0 cm) | 2.04 (1.05-3.96) | 0.034 | 532.85 | 1 [reference] |
| ALN status (positive vs. negative) | 2.03 (1.15-3.58) | 0.015 | ||
| ER (negative vs. positive) | 2.05 (1.15-3.66) | 0.015 | ||
| TILs (low vs. high) | 2.63 (1.44-4.81) | 0.002 | ||
| TRAG mutation (yes vs. no) | 3.45 (1.92-6.23) | < 0.001 | ||
| Model 5: CP features + TILs + CNA + TRAG | ||||
| Tumor size (> 2.0 cm vs. ≤ 2.0 cm) | 2.04 (1.05-3.96) | 0.035 | 533.85 | 0.377 |
| ALN status (positive vs. negative) | 2.03 (1.15-3.57) | 0.014 | ||
| ER (negative vs. positive) | 2.03 (1.13-3.62) | 0.017 | ||
| TILs (low vs. high) | 2.57 (1.40-4.71) | 0.002 | ||
| CNA (high vs. low) | 1.28 (0.74-2.23) | 0.380 | ||
| TRAG mutation (yes vs. no) | 3.34 (1.85-6.05) | < 0.001 | ||
DFS: Disease-free survival; CP: clinicopathologic parameter; HR: hazard Ratio; CI: confidence interval; AIC: Akaike information criterion; LRT: likelihood ratio test; ALN: axillary lymph node; ER: estrogen receptor; TILs: tumor-infiltrating lymphocytes; CNA: copy number alteration; TRAG: trastuzumab response-associated gene. TRAG: We derived a 15-gene signature associated with trastuzumab response (FLG, MAP1A, ASPM, MEN1, PTEN, SMAD2, SCN7A, BRCA1, CTNNA1, FYN, HRNR, MRE11, RNF43, DCTN1, and PCLO). **Two-sided P < 0.001.